Are BTK and PLCG2 mutations important and enough for ibrutinib resistance in chronic lymphocytic leukemia?All this knowledge has presented new Views that are increasingly being exploited therapeutically with novel, targeted brokers and management techniques. In this evaluation we provide an outline of those novel advances and emphasize inquiries an